Loading the company…
Loading the company…
㈜엔비케이제약
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Chungnam, founded in 2003. Industry: Bio & Pharma. Revenue for 2025 was ₩9.1bn. It has 41 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2023-11-15 · latest registration 2022-01-14 · newest first
본 발명은 용출률과 안정성이 향상된 밀크시슬 함유 경구 투여용 제제 및 그 제조방법에 관한 것으로서, 보다 상세하게는 난용성 약물인 밀크시슬을 포함하는 제1 과립부와 밀크시슬을 가용화시킬 수 있는 알칼리화제를 포함하는 제2 과립부를 물리적으로 구분하여 포함함으로써 밀크시슬의 용출률이 향상되면서도 우수한 제제 안정성을 나타내는 밀크시슬 함유 경구 투여용 제제 및 그 제조방법에 관한 것이다.
본 발명은 아이비엽 추출물과 금은화 추출물의 혼합물, 또는 아이비엽과 금은화 혼합 추출물을 유효성분으로 함유하는 호흡기 질환의 예방 및 치료용 조성물에 관한 것으로, 본 발명의 유효성분은 거담활성, 진해활성 및 항염증 효과가 우수하여 호흡기 질환의 예방 및 치료에 효과적인 약학 조성물 및 건강기능식품으로 사용될 수 있다.
난용성의 밀크시슬을 계면활성제 및 용해증진제를 포함하는 혼합물로 흡착시킴으로써 밀크시슬의 용출율을 극대화 시켜 밀크시슬의 용출율 및 안정성이 향상된 정제, 조성물 및 그 제조 방법에 관한 것이다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 3 of 3 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 11.0 | 9.1 |
| Cost of sales | 7.4 | 7.1 |
| Gross profit (loss) | 3.6 | 2.0 |
| Selling, general and administrative expenses | 3.5 | 4.0 |
| Operating income (loss) | 0.1 | (2.0) |
| Non-operating income | 1.2 | 0.2 |
| Other gains | 1.2 | 0.0 |
| Finance income | 0.0 | 0.0 |
| Other | — | 0.1 |
| Non-operating expenses | 2.1 | 1.3 |
| Other losses | 0.4 | 0.1 |
| Finance costs | 1.4 | 1.2 |
| Other | 0.3 | — |
| Profit (loss) before tax | (0.8) | (3.1) |
| Net income (loss) | (0.8) | (3.1) |
Revenue ₩9.1bn, down 17.8% YoY.
Operating margin -22.1% (prior 0.5%).
Net income ₩-3.1bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.